SCHEMBL4050654

SCHEMBL4050654

Brc1cnc2nc(-c3cccc(Oc4ccccc4)c3)[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.52
DHODH Q02127 1/20 0.51
CHEK2 O96017 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
ESR1 P03372 1/20 0.47
MAPK13 O15264 1/20 0.42
GCGR P47871 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
MAPT P10636 1/20 0.42
ATM Q13315 1/20 0.42
GRIN2D O15399 3/20 0.42
GRIN3B O60391 3/20 0.42
GRIN1 Q05586 3/20 0.42
GRIN2A Q12879 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063060 0.87 DHODH (0.53) AURKADHODHCHEK2MAPK13GCGR
SCHEMBL4054555 0.86 AURKA (0.67) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL1667430 0.85 AURKA (0.68) AURKADHODHSMN1; SMN2RXFP1ESR1
SCHEMBL4058201 0.84 SMN1; SMN2 (0.55) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4240248 0.84 ESR1 (0.49) AURKADHODHSMN1; SMN2LMNAHTT
SCHEMBL4059124 0.83 AURKA (0.53) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4055350 0.82 SMN1; SMN2 (0.53) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4060144 0.81 SMN1; SMN2 (0.52) AURKACHEK2SMN1; SMN2LMNAHTT
SCHEMBL4052740 0.81 SMN1; SMN2 (0.49) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4051984 0.81 SMN1; SMN2 (0.55) AURKASMN1; SMN2LMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885DHODH 3172/4885CHEK2 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.